RxDoctor Payments DataLook up a doctor →

Tracy Bridges, MD

Allergy & Immunology · Albany, GANPI 1386749117

Payments from drug & device makers

$1,529,388in general payments, 2019–2025

Across 1,124 payments — averaging $1360.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$385K
  • LEO Pharma AS$268K
  • Grifols Therapeutics LLC$248K
  • AbbVie$179K
  • Pfizer$105K
  • Eli Lilly$90K
  • plus $254K from 36 others

What the payments were for

  • Consulting fees$6,7372%
  • Speaking & faculty fees$319,85888%
  • Travel & lodging$17,7815%
  • Food & beverage$19,7785%
  • Education$1030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,529,388 in reported general payments places this provider in the 95th percentile of 107 allergy & immunology providers in Georgia.

See all allergy & immunology providers in Georgia

Medicare billing

Part B allowed, 2024
$235,082
Medicare patients
320
Services billed
12,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HaegardaC1 Esterase Inhibitor26$839,912
Dupixent SyringeDupilumab99$389,003
TezspireTezepelumab-Ekko54$234,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter218$172,054
XolairOmalizumab50$165,528
HizentraImmun Glob G(Igg)/Pro/Iga 0-5031$161,904
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5012$125,699
Breztri AerosphereBudesonide/Glycopyr/Formoterol79$56,759
Dupixent PenDupilumab14$49,107
GammakedImmune Globul G/Gly/Iga Avg 4611$45,204
Breo ElliptaFluticasone/Vilanterol102$43,196
Arnuity ElliptaFluticasone Furoate134$36,316
SymbicortBudesonide/Formoterol Fumarate98$31,348
Spiriva RespimatTiotropium Bromide23$19,655
Azelastine Hcl549$17,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHaegarda, Hizentra$6,767$1,001,81657 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$385,070$322,552231 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$1,769$264,277488 claims
Genentech, Inc.Xolair$4,665$165,52850 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$10,552$125,69912 claims
Boehringer IngelheimSpiriva Respimat$7,513$19,65523 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$3,682$9,35923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 107 allergy & immunology providers in Georgia.

Other allergy & immunology in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →